Form 4: Elanco Animal Health Director R. David Hoover Acquires 25,000 Shares

Director R. David Hoover of Elanco Animal Health Inc. reports the acquisition of 25,000 shares of common stock at a price of $10.9023 per share on March 5, 2025.

Summary

• On March 5, 2025, R. David Hoover, a director of Elanco Animal Health Inc., purchased 25,000 shares of the company's common stock.
• The shares were acquired at a price of $10.9023 per share.
• Following the transaction, Hoover directly owns 96,459 shares and indirectly owns 210,000 shares through a revocable trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The purchase of shares by a director is generally viewed as a positive sign, but the filing itself is a routine regulatory requirement.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued or that the company is expected to perform well in the future. Investors often monitor Form 4 filings to gain insights into the sentiment of company insiders.

Comparison to Industry Standards

• Comparing Hoover's transactions to those of other directors in similar animal health companies could provide context.
• For example, Zoetis (ZTS) and IDEXX Laboratories (IDXX) are major players in the animal health industry.
• Analyzing the frequency and size of insider transactions in these companies could offer a benchmark for evaluating the significance of Hoover's purchase.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates